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Abstract
Objective. To determine the concordance between RIA and bridging ELISA at detecting anti-drug anti-
bodies (ADAbs) in the context of random adalimumab levels and investigate the additional clinical utility of
detecting ADAbs in RA patients who test ADAb positive by RIA and negative by ELISA.
Methods. ADAb levels were determined using RIA and bridging ELISA in 63 adalimumab-treated RA
patients (159 samples). Immunogenicity concordance was determined using receiver operating character-
istic curves. To determine the additional clinical value provided by a positive RIA in the presence of
negative ELISA, association between treatment response (DAS28), adalimumab drug levels and
ADAbs was evaluated longitudinally using generalized estimating equation.
Results. Of the 60 RIA+ samples (n = 31 patients), 19 (n = 10 patients) were also ELISA+, corresponding to
31.7% of samples. Area under the curve for detecting ADAbs using ELISA (compared with RIA) using
receiver operating characteristic curves was 0.65 (95% CI: 0.59, 0.71); this increased to 0.91 (95% CI:
0.81, 0.99) if ADAbs were5100 AU/ml using RIA. In RIA+/ELISA patients, adalimumab levels were asso-
ciated with DAS28 over 12 months [regression coefficient: 0.098 (95% CI: 0.043, 0.15), P<0.0001] and
while ADAbs were significantly associated with drug level, they were not directly associated with DAS28
over 12 months [b coefficient: 0.00083 (95% CI: 0.0038 to 0.0054), P = 0.72].
Conclusion. ADAbs were detected using ELISA more frequently when present in high titres as measured
by RIA. In RIA+/ELISA patients, only drug levels were significantly associated with treatment response.
Although ADAbs were not independently associated with treatment response, they may be helpful in
determining the aetiology of low drug levels.
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Rheumatology key messages
. Compared with RIA, ELISAs demonstrated good specificity but poor sensitivity in RA patients with random drug
level measurements.
. In RIA+/ELISA patients, only drug levels were significantly associated with treatment response.
. A sensitive anti-drug antibody assay is useful to determine the aetiology of low drug levels in RA.
Introduction
In up to 40% of RA patients treated with an anti-TNF ther-
apy, the drugs fail to control disease activity adequately
due to primary or secondary inefficacy (loss of response).
One explanation is immunogenicity leading to the devel-
opment of anti-drug antibodies (ADAbs). ADAbs may
reduce the efficacy of anti-TNF treatment, by competing
for the cytokine-binding site (neutralizing antibodies) or by
promoting more rapid drug clearance (non-neutralizing/
binding antibodies), leading to sub-therapeutic drug
levels. The majority (>97%) of ADAbs to adalimumab
are neutralizing [1], thus immediately antagonizing TNF
inhibition.
Bridging ELISAs and RIA have been most commonly
utilized in clinical studies for ADAb detection [2, 3].
ELISAs have the advantages of low cost, high throughput
and ease of automated testing in most clinical labora-
tories. However, the bridging ELISA may be less tolerant
to the effects of free circulating drug as both Fab arms of
the antibody need to be available for binding to the drug
coated on the plate, as well as the biotinylated drug for
detection. RIA uses protein A Sepharose to capture ADAb
from the patient’s serum, followed by addition of radiola-
belled drug, which binds to drug-specific antibodies.
Fluid-phase RIA is not influenced by artefacts induced
by solid-phase adsorption of proteins, and thus has the
advantage over solid-phase ELISAs, better reflecting the
situation in vivo. The RIA is more specific than the bridging
ELISA, is less prone to drug interference and can also
detect certain IgG subclasses, namely IgG1, IgG2 and
IgG4 (which are functionally monovalent [only bound to
‘antigen’] and which have a greater potential for neutral-
ization [4]). Radioisotopes, however, make RIA more com-
plex to set up and expensive than ELISA, which limits
widespread use.
We have previously demonstrated that ADAbs to mono-
clonal antibodies, as measured by RIA, lead to low drug
levels and are important predictors of poor treatment re-
sponse. This held true even in the presence of free drug
and when assessed at random points in the treatment
cycle (herein referred to as random drug levels, which
are not necessarily collected before the patient is due
the next dose) [5]. A combination of ADAbs to adalimu-
mab and low drug levels at 3 months generated an area
under the receiver operating characteristic (ROC) curve
(AUC) of 0.71 (95% CI: 0.57, 0.85) for lack of EULAR re-
sponse at 12 months, suggesting good predictive utility
for clinical practice. To implement immunogenicity testing
successfully in a clinical setting, a less expensive and
simpler test, such as an ELISA, would be preferable. In
a practical clinical setting, trough levels in blood samples
taken immediately prior to next drug dosing, although
maximally informative, are difficult to obtain. While our
previous work demonstrated the utility of random samples
in the context of RIA ADA testing, the clinical value of
ELISA in this setting is unknown [5]. Our aims were to
determine the concordance between RIA and a commer-
cially available ELISA in adalimumab-treated RA patients,
in the context of random blood samples, and evaluate the
additional clinical utility of ADAbs that are detectable by
RIA but not by ELISA.
Methods
Study population
Patients were recruited to a prospective observational
cohort study, the Biologics in Rheumatoid Arthritis
Genetics and Genomics Study Syndicate [6], between
November 2008 and March 2013. From the total cohort,
patients were selected according to the following inclu-
sion criteria: RA according to the revised ACR 1987 cri-
teria [7], active disease indicated by a DAS28 55.1
despite earlier treatment with at least two DMARDs
including MTX; patients of Caucasian descent; about to
be initiated on adalimumab (40 mg every fortnight). At
baseline and following initiation of therapy, patients had
serum samples collected with disease activity measured
at 3, 6 and 12 months. Treatment response was deter-
mined using change in DAS28CRP from baseline
(DAS28, defined as baseline DASCRP score-time point
3, 6 and 12 months DASCRP score). An improvement with
treatment therefore would lead to a positive value
DAS28CRP. EULAR response criteria were calculated
for descriptive purposes [8]. All participating patients pro-
vided written informed consent and the study was
approved by a multicentre ethics committee (COREC
04/Q1403/37).
Measurement of ADAbs and drug levels
All adalimumab samples (n = 414) in 160 patients were
tested for ADAbs using RIA (Sanquin) and drug levels as
previously described [5, 9]. Drug levels were measured
using sandwich ELISAs manufactured by Progenika
Biopharma, Derio, Spain. Additionally in 159 samples in
63 patients, which included all ADAb positive patients as
well as a random selection of negative ADAb patients,
serum ADAbs were measured using a commercially avail-
able bridging ELISA (Progenika Biopharma).
Measurement of ADAbs and drug levels was performed
in-house according to the manufacturer’s instructions.
Patients were deemed to be ADAb positive by ELISA if
levels detected were 53.5 AU/ml and ADAb positive by
RIA if levels were >12 AU/ml, as per the manufacturer.
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Statistics
Between group comparisons were evaluated using
MannWhitney U (Wilcoxon) statistics and chi-squared
tests as appropriate. Non-parametric Spearman’s correl-
ations were determined between adalimumab drug level
and ADAb using both RIA and ELISA, as well as ADAbs
detected using both techniques. Kappa coefficient values
were calculated for comparisons between both techniques.
Area under the ROC curve (AUC) was determined to test the
sensitivity of ELISA at detecting ADAbs when compared
with detection using RIA. The generalized estimating equa-
tion (GEE) model with an identity link for longitudinal con-
tinuous outcomes was used to test the association between
treatment response, drug and ADAb levels in patients who
had ADAbs detected using RIA but not ELISA, to assess the
value of detecting additional RIA positive samples.
Statistical analyses were performed using STATA for
Windows version 13.0 (Stata Corp., College Station, TX,
USA) and Graph Pad Prism 6.04 for generation of Figure 1.
Results
One hundred and fifty-nine samples in 63 patients were
tested for ADAbs to adalimumab using both techniques.
Of the 60 samples that were positive using RIA (n = 31 pa-
tients) [5], 31.7% tested positive using ELISA (19 samples in
10 patients). In patients in whom ADAbs were detected
using an ELISA, titres continued to increase for the following
3 months (Table 1). Spearman’s correlation with adalimu-
mab drug levels was as follows: ELISA rs0.45 (P< 0.001);
RIA rs 0.51 (P< 0.001). This demonstrated an inverse as-
sociation between drug and ADAb levels using both tech-
niques. Overall correlation between ADAbs detected by
ELISA and RIA was moderate, but much stronger when
high titre ADAbs were detected using RIA at levels
>100 AU/ml (Table 1). Similarly the AUC for detecting
ADAbs by performing an ELISA (compared with RIA)
using ROC curves was 0.65 (95% CI: 0.59, 0.71); this
increased to an AUC of 0.91 (95% CI: 0.81, 0.99) in samples
in which ADAbs were detected at concentrations of
5100 AU/ml using RIA [18 samples with ADAbs
5100 AU/ml (range 100111 000)]. Of the 21 samples test-
ing positive using ELISA, the majority (n = 15; 71.4%) were
in samples with ADAb titres of 5100 AU/ml using RIA.
Kappa coefficient, sensitivity, specificity, and positive and
negative predictive values are detailed in Table 1.
Adalimumab levels were significantly different in pa-
tients who had ADAbs compared with patients who did
not, using either method at 6 and 12 months (Table 1).
Five patients had positive ADAbs using ELISA at 3
months (compared with 19 patients using RIA) (Table 1).
Only four samples yielded both circulating drug and
ADAbs by ELISA whereas the majority of samples that
tested positive for ADAbs by RIA also demonstrated cir-
culating drug (Fig. 1). High titre ADAbs (>100 AU/ml) were
associated with absent drug levels using either technique.
Forty samples (in 25 individual patients) had ADAbs de-
tected using RIA, but not using ELISA, the characteristics
of which are shown in Table 1. To assess the effect of
ADAbs detected using RIA on drug level longitudinally
over 12 months, our previous work demonstrated a
strong inverse association between adalimumab drug
levels and ADAb status using the GEE: regression coeffi-
cient (RC) 4.77 [95% CI: 6.39 to 3.15], P< 0.0001 [5].
To quantify how much of the point estimate was attributed
to these 40 samples, which would have been missed
using ELISA, we performed an additional GEE model
using only these patients (Table 1). This shows that the
RC is lower (fewer samples and lower ADAb titre in this
model) but continues to be highly significant [RC 3.70
(95% CI: 5.01 to 2.32), P< 0.0001]. Adalimumab drug
levels in these samples continued to be significantly asso-
ciated with DAS28 over the course of 12 months.
However, in the univariate analysis, ADAb level was no
longer associated directly with treatment response
(Table 1). Therefore the use of circulating drug levels
alone provides a useful indicator of future treatment
effect but detection of ADAb positivity in non-trough
blood samples using RIA, otherwise missed using
ELISA, provides additional value to the clinician interpret-
ing the aetiology of a low adalimumab drug level.
Interestingly two samples tested positive using ELISA, but
were negative using RIA (supplementary Fig. S1, available at
RheumatologyOnline). In one patient ADAb levels measured
14.8 AU/ml, with undetectable adalimumab levels, but the
patient was found to have a good EULAR response at 12
months. It is possible that this patient (on MTX 10 mg/
week) may have reached drug-free remission, no longer
requiring an anti-TNF agent. In the second patient, ADAb
levels of 49.3 AU/ml were detected at 3 months only, with
an adalimumab level of >12 mg/ml (in association with a
moderate EULAR response). These appear to be false-posi-
tive or transient antibodies, of no clinical significance.
Discussion
Our study demonstrates, for the first time, utility of testing
for ADAbs using ELISA in the context of random rather
than trough drug levels, random levels being more prac-
tical to obtain in clinical practice. Of the two tests studied,
ADAb detection using RIA was more sensitive in the pres-
ence of free drug compared with ELISA. Patients who had
ADAbs detected using ELISA were more likely to have
high titre ADAbs (>100 AU/ml) as detected by RIA. In pa-
tients in whom ADAbs were detected using RIA but not
ELISA, ADAb levels failed to reach statistical significance
independently in association with treatment response.
However adalimumab levels continued to remain signifi-
cantly associated with treatment response longitudinally
across all time points and therefore were confirmed to be
an important prognostic indicator.
Strengths of this study include the prospective serial
sampling and well-characterized cohort of patients with
treatment outcome measures. Previous studies that
have tested for immunogenicity and concordance be-
tween tests have measured these in trough adalimumab
samples [10, 11], but it is recognized that obtaining these
in clinical practice is more challenging to perform and has
practical implications for both service delivery and for the
2052 www.rheumatology.oxfordjournals.org
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patients themselves. Although we compared ADAbs de-
tected by ELISA with those detected by RIA (being the two
more commonly performed tests in immunogenicity stu-
dies), currently there is no gold standard for measurement
of ADAbs, detection of which may be influenced by a
number of factors [12]. Newer, more drug tolerant
assays continue to emerge that may be more suited for
ADAb detection in the context of random drug levels, such
TABLE 1 Patient characteristics and concordance between RIA or ELISA for anti-drug antibody testing
Adalimumab drug levels in patients stratified by anti-drug antibody status using RIA and ELISA
Time point
Variable
3 months 6 months 12 months
Median (IQR) P-valuea Median (IQR) P-value Median (IQR) P-valuea
Adalimumab drug level if ADAb
negative using RIA, mg/ml
12.0 (11.412.0) <0.001 12.0 (11.912) <0.001 12 (7.912) <0.001
Adalimumab drug level if ADAb
positive using RIA, mg/ml
4.6 (0.98.2) 2.1 (08.7) 1.7 (06.8)
ADAb level using RIA, AU/mlb 37 (2395) — 48.5 (18200) — 25 (212,800) —
Adalimumab drug level if ADAb
negative using ELISA, mg/ml
9.9 (5.212) 0.08 11.0 (4.712) <0.001 4.6 (1.8 11.3) <0.001
Adalimumab drug level if ADAb
positive using ELISA, mg/ml
1.6 (0.28.2) 0 (00.03) 0 (00)
ADAb level using ELISA, AU/ml 59.1 (49.3111.5) — 141.6 (38.9312.2) — 2000 (14.82000) —
Patient characteristics in those who are ADAb positive using both test vs patients who are ADAb positive
using RIA and ADAb negative using ELISA
Variable
ADAb positive using both
tests (RIA and ELISA)b
ADAb positive using RIA and
ADAb negative using ELISAc P-valuea
ADAb level (using RIA), median (IQR), AU/ml 430 (1204000) 25.0 (18.049.5) <0.001
Adalimumab drug level, median (IQR), mg/ml 0 (00.20) 6.1 (1.4 9.5) <0.001
MTX use, patients, n (%) 5 (50) 12 (48) 0.98
MTX dose, median (IQR), mg/week 15 (7.522.5) 15 (1022.5) 0.81
Disease duration median (IQR), years 12 (6.218.3) 14 (7.820.1) 0.63
GEE analysis in patients who were ADAb negative using ELISA and ADAb positive using RIAc
Variable Regression coefficient (95% confidence intervals) P-value
Association between adalimumab drug
levels and ADAbs using GEE
3.15 (4.41,  1.88) <0.0001
Association between treatment response (DAS28)
and adalimumab drug level
0.098 (0.043, 0.15) <0.0001
Association between treatment response (DAS28)
and ADAb level
0.00083 (0.0038, 0.0054) 0.72
Concordance between RIA and ELISA Value (95% Confidence Intervals) P-value
Kappa coefficient (95% CI) 0.35 (0.21, 0.48) <0.001
Spearman’s correlation coefficient (all samples) 0.54 (0.42, 0.64) <0.001
Spearman’s correlation coefficient (high titre ADAbs
detected using RIA, 5100 AU/ml)
0.86 (0.66, 0.95) <0.001
AUC for detecting ADAbs using ELISA (all samples) 0.65 (0.59, 0.71)
AUC for detecting ADAbs using ELISA high titre ADAbs
detected using RIA, 5100 AU/ml)
0.91 (0.81, 0.99)
Sensitivity of ELISA (95% CI) 32.2% (20.6, 45.6)
Specificity of ELISA (95% CI) 98% (93.0, 99.8)
Positive predictive value 90.5% (69.6, 98.8)
Negative predictive value 71.0% (62.7, 78.4)
Adalimumab drug levels could be detected up to a maximal concentration of 12 mg/ml. MTX dose and disease duration are
the described characteristics in the table as these were the two factors associated with ADAb formation in our cohort [5]. aP-
value represents the significance of differences between groups using chi-squared tests for categorical outcomes and
Wilcoxon rank sum tests for continuous variables. b10 patients, 19 samples. c25 patients, 40 samples. ADAb: anti-drug
antibodies; AU: arbitrary units; AUC: area under the curve; GEE: generalized estimating equation.
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as the pH-shift anti-idiotype antigen binding test, acid-dis-
sociation RIA and temperature-shift RIA [13]. However,
these tests are cumbersome and expensive to perform
on a large clinical scale, are available in specialist centres
only, and their utility in a clinical context is not yet known.
Our work highlights the importance of interpreting ADAb
results in the context of simultaneously measured drug
levels. The latter appears to be the more important of
the two tests at predicting treatment response, especially
in patients with lower ADAb titres. It is important to note
that detection of ADAbs need not significantly influence
treatment response if sufficient drug is still in circulation,
which may explain results in RIA+/ELISA patients. While
we acknowledge the limited power of our study, measure-
ment of ADAbs using sensitive assays may provide valu-
able insight into the aetiology of low drug levels in
adalimumab-treated patients. In a patient with a low cir-
culating drug level, immunogenicity testing helps to deter-
mine causation, which in turn should optimize future
management of the disease. For instance if ADAbs are
detected in the context of a low drug level, switching to
a less immunogenic drug could be beneficial [14] whereas
switching to another mAb may trigger another immuno-
genic response and subsequent inefficacy [15]. These
patterns may be missed when testing for ADAbs by
ELISA in random samples and our previous work demon-
strated that a low drug level may not always result from
immunogenicity. An isolated low drug level (in the ab-
sence of detectable ADAbs) may be due to factors such
as high BMI or poor adherence to therapy, both of which
require different strategies compared with those for pa-
tients with detectable ADAbs [9].
In conclusion, when testing for immunogenicity at
random points in the biologic treatment cycle, ELISA
was less sensitive than RIA, with better concordance be-
tween the assays when ADAb titres were high (>100 AU/
ml by RIA). Testing non-trough samples using ELISA can
still demonstrate ADAbs but may be less clinically useful
due to the high proportion of false-negative samples,
most likely due to the poor tolerance of ELISA to free
drug. Adalimumab drug level was the most important pre-
dictor of treatment response in patients who had ADAbs
detected using RIA but not ELISA. However, a more drug
tolerant assay such as RIA enables interpretation of the
aetiology of low non-trough drug levels.
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